Luisa Laria-Castro

Sevilla, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease.

Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease.

Journal: Therapeutic advances in gastroenterology

Published: March 14, 2024

High serum levels of ustekinumab are associated with better clinical outcomes during maintenance treatment for inflammatory bowel disease.

High serum levels of ustekinumab are associated with better clinical outcomes during maintenance treatment for inflammatory bowel disease.

Journal: Therapeutic advances in gastroenterology

Published: February 15, 2024

Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.

Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.

Journal: Inflammatory bowel diseases

Published: February 05, 2024

Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.

Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.

Journal: Therapeutic advances in gastroenterology

Published: May 03, 2023

Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results.

Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results.

Journal: Revista espanola de enfermedades digestivas

Published: September 14, 2021

Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.

Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.

Journal: Revista espanola de enfermedades digestivas

Published: May 05, 2021

Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study.

Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study.

Journal: Gastroenterologia y hepatologia

Published: March 01, 2021

Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.

Ustekinumab in Crohn's disease: real-world outcomes and predictors of response.

Journal: Revista espanola de enfermedades digestivas

Published: January 04, 2021

Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results.

Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results.

Journal: Revista espanola de enfermedades digestivas

Published: December 29, 2020

Autoimmune Encephalitis During Treatment With Adalimumab: A Case Report in Crohn's Disease.

Autoimmune Encephalitis During Treatment With Adalimumab: A Case Report in Crohn's Disease.

Journal: Inflammatory bowel diseases

Published: November 19, 2020

Index of the Mayo Endoscopy and Ulcerative Colitis Endoscopy Index of Severity: are they equally valid?

Index of the Mayo Endoscopy and Ulcerative Colitis Endoscopy Index of Severity: are they equally valid?

Journal: Revista espanola de enfermedades digestivas

Published: October 15, 2020

Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practice.

Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practice.

Journal: Revista espanola de enfermedades digestivas

Published: September 21, 2020

Showing 1-12 of 34

Last Updated: 09/26/2026